Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka) Kesatuan Eropah - Finland - EMA (European Medicines Agency)

lenalidomide krka d.d. novo mesto (previously lenalidomide krka)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - immunosuppressantit - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) on tarkoitettu aikuisille potilaille, joilla on aiemmin hoitamaton multippeli myelooma, jotka eivät ole oikeutettuja siirto. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) on tarkoitettu aikuisille potilaille, joilla on aiemmin hoitamaton multippeli myelooma, jotka eivät ole oikeutettuja siirto. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto) Kesatuan Eropah - Finland - EMA (European Medicines Agency)

lenalidomide krka (previously lenalidomide krka d.d. novo mesto)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - immunosuppressantit - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) on tarkoitettu aikuisille potilaille, joilla on aiemmin hoitamaton multippeli myelooma, jotka eivät ole oikeutettuja siirto. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 ja 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) on tarkoitettu aikuisille potilaille, joilla on aiemmin hoitamaton multippeli myelooma, jotka eivät ole oikeutettuja siirto. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 ja 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

IMATINIB KRKA D.D. 400 mg dispergoituva tabletti Finland - Finland - Fimea (Suomen lääkevirasto)

imatinib krka d.d. 400 mg dispergoituva tabletti

krka, d.d., novo mesto krka, d.d., novo mesto - imatinibi mesylas - dispergoituva tabletti - 400 mg - imatinibi

Atazanavir Krka Kesatuan Eropah - Finland - EMA (European Medicines Agency)

atazanavir krka

krka, d.d., novo mesto - atazanavir (as sulfate) - hiv-infektiot - antiviraalit systeemiseen käyttöön - atatsanaviiri krka-kapseleita, co-valmiste yhdessä pieniannoksisen ritonaviirin kanssa on tarkoitettu hiv-1-tartunnan saaneille aikuisille ja lapsipotilaille suositellaan 6-vuotiaille ja sitä vanhemmille yhdessä muiden antiretroviraalisten lääkevalmisteiden. perustuu käytettävissä virologinen ja kliininen tietoja aikuisille potilaille, mitään hyötyä ei ole odotettavissa potilailla, joilla on kantoja, jotka kestävät useita proteaasi-inhibiittoreita (≥ 4 pi-mutaatiota). valinta atatsanaviiri krka-hoitoa kokenut aikuis-ja lapsipotilailla olisi perustuttava yksittäisten virusresistenssitestauksen ja potilaan hoidon historia.

TELDIPIN 40 mg / 5 mg tabletti Finland - Finland - Fimea (Suomen lääkevirasto)

teldipin 40 mg / 5 mg tabletti

krka, d.d., novo mesto krka, d.d., novo mesto - amlodipini besilas,telmisartanum - tabletti - 40 mg / 5 mg - telmisartaani ja amlodipiini

TELDIPIN 40 mg / 10 mg tabletti Finland - Finland - Fimea (Suomen lääkevirasto)

teldipin 40 mg / 10 mg tabletti

krka, d.d., novo mesto krka, d.d., novo mesto - telmisartanum,amlodipini besilas - tabletti - 40 mg / 10 mg - telmisartaani ja amlodipiini

TELDIPIN 80 mg / 5 mg tabletti Finland - Finland - Fimea (Suomen lääkevirasto)

teldipin 80 mg / 5 mg tabletti

krka, d.d., novo mesto krka, d.d., novo mesto - telmisartanum,amlodipini besilas - tabletti - 80 mg / 5 mg - telmisartaani ja amlodipiini

TELDIPIN 80 mg / 10 mg tabletti Finland - Finland - Fimea (Suomen lääkevirasto)

teldipin 80 mg / 10 mg tabletti

krka, d.d., novo mesto krka, d.d., novo mesto - amlodipini besilas,telmisartanum - tabletti - 80 mg / 10 mg - telmisartaani ja amlodipiini

VALAROX 10 mg / 80 mg tabletti, kalvopäällysteinen Finland - Finland - Fimea (Suomen lääkevirasto)

valarox 10 mg / 80 mg tabletti, kalvopäällysteinen

krka, d.d., novo mesto krka, d.d., novo mesto - valsartanum,rosuvastatinum calcicum - tabletti, kalvopäällysteinen - 10 mg / 80 mg - rosuvastatiini ja valsartaani

VALAROX 20 mg / 80 mg tabletti, kalvopäällysteinen Finland - Finland - Fimea (Suomen lääkevirasto)

valarox 20 mg / 80 mg tabletti, kalvopäällysteinen

krka, d.d., novo mesto krka, d.d., novo mesto - rosuvastatinum calcicum,valsartanum - tabletti, kalvopäällysteinen - 20 mg / 80 mg - rosuvastatiini ja valsartaani